APP-401

APP-401 and APP-069 are preclinical small molecule drug candidates being developed by Aphios Corporation for the treatment of HIV/AIDS. These compounds were discovered through a high-throughput screening of over 10,000 marine microorganism fractions, utilizing cytoprotection and cytotoxicity assays to identify agents with anti-HIV activity. The development of these candidates leverages Aphios's proprietary supercritical fluid technology (CXP) for the extraction and purification of natural products from marine biodiversity. While the specific molecular targets and mechanisms of action for APP-401 and APP-069 have not been publicly disclosed, they represent lead assets in the company's infectious disease pipeline. Aphios also utilizes nanotechnology platforms, such as nanosomes and nanospheres, which may be applied to the formulation and delivery of these marine-derived therapeutics.

Other names

Aphios-HIV-small molecule-HIV/AIDS